Core Insights - Moderna has reached a settlement agreement with Genevant Sciences and Arbutus Biopharma, resolving a patent dispute related to lipid nanoparticle technology used in its COVID-19 and RSV vaccines [1][6]. Financial Implications - The settlement requires Moderna to make an upfront payment of $950 million by July 8, 2026, with an additional potential payment of up to $1.3 billion if its appeal to the Federal Circuit is unsuccessful [2][6]. - Moderna anticipates recording a charge of $950 million in Q1 2026 related to this settlement and projects to end 2026 with cash and cash equivalents between $4.5 billion and $5 billion [7]. Market Reaction - Following the announcement of the settlement, Moderna's shares rose nearly 6% in after-market trading, reflecting positive investor sentiment regarding the terms of the settlement, which are considered a small fraction of the company's vaccine sales during the pandemic [3]. Licensing Agreement - As part of the settlement, Moderna will receive a global, non-exclusive license to Genevant/Arbutus' lipid nanoparticle delivery technology and a covenant not to sue for certain patents related to Moderna's products [3][6]. Liquidity Outlook - Moderna retains access to up to $900 million under its existing credit facility, which would increase its total projected liquidity to between $5.4 billion and $5.9 billion by the end of 2026 [7]. Ongoing Legal Context - Arbutus and Genevant are also involved in a patent dispute with Pfizer and BioNTech regarding the use of lipid nanoparticle technology in their COVID-19 vaccine, Comirnaty, which is still ongoing [8].

Core Viewpoint - Lupin has reached a settlement with Astellas Pharma to resolve a patent infringement dispute regarding its Mirabegron product, agreeing to pay a total of $90 million, which includes a prepaid option payment of $75 million and a prepaid per-unit license fee for each unit sold until September 2027 [1][5]. Group 1: Settlement Details - The settlement amount totals $90 million, comprising a prepaid option payment of $75 million and additional fees based on product sales [1][5]. - The financial and commercial terms of the settlement remain confidential [2][5]. - The agreement resolves pending litigation with Astellas, allowing Lupin to continue marketing and selling Mirabegron in the U.S., thus eliminating a significant legal hurdle [2][5]. Group 2: Impact on Business Operations - The settlement provides closure to the patent dispute initially disclosed by Lupin in April 2025 [4][5]. - This resolution enhances visibility on the near-term commercial trajectory of the Mirabegron product [4][5].